Vanda Pharmaceuticals | VNDA - Ebitda

Stock Price
7.44
Daily Change
0.02 0.27%
Monthly
0.40%
Yearly
56.63%
Q1 Forecast
4.24

Vanda Pharmaceuticals reported $-8.31M in EBITDA for its fiscal quarter ending in December of 2024.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Agios Pharmaceuticals USD -125.8M 20.45M Jun/2025
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Alnylam Pharmaceuticals USD 381.78M 362.95M Sep/2025
Anika Therapeutics USD -2.69M 4.73M Mar/2025
Arrowhead Research USD 64.2M 223.53M Sep/2025
AstraZeneca USD 5.23B 272M Sep/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Esperion Therapeutics USD -27.51M 9.5M Sep/2023
Halozyme Therapeutics USD 248.25M 22.74M Sep/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Insmed USD -297.13M 71.11M Jun/2025
J&J USD 9.52B 389M Sep/2025
Ligand Pharmaceuticals USD 20.9M 61.44M Jun/2025
Merck USD 8.39B 1.97B Sep/2025
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Moderna USD -208M 552M Sep/2025
Novartis USD 5.84B 235M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
PTC Therapeutics USD -33.11M 1B Jun/2025
Puma Biotechnology USD 729K 11.36M Jun/2024
Sanofi EUR 4.84B 2.95B Sep/2025
Takeda JPY 448.13B 173.98B Dec/2025
Teva Pharmaceutical Industries USD 1.64B 243M Dec/2025
Ultragenyx Pharmaceutical USD -91.34M 35.09M Jun/2025
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024
Veracyte USD 39.73M 3.96M Sep/2025